Estrella nears completion of SPAC listing

Estrella Immunopharma nears completion of SPAC listing

The developer of T-cell cancer therapies is based in California, but says it ‘may be subject to risks’ due to its numerous China connections Key Takeaways: Estrella Immunopharma is nearing…

Lepu Biopharma Marches Towards First Sales as Costs Mount

Company’s Puyouheng cancer immunotherapy drug was approved for two indications in China, becoming its first commercialized product Key Takeaways: Lepu Biopharma will incur more operational costs as it builds up…

Burning Rock Localizes as Investors Grow Impatient

Cancer testing company reported a widening loss in the first quarter as it spent heavily to build up its localized business model of providing services through partner hospitals Key Takeaways:…